环[b]双作为具有抗白血病活性的新型抗微管体剂
Hugo Passos Vicari1, Ralph da Costa Gomes2, Keli Lima3
1Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
概括
新型化合物C2E1通过破坏癌细胞功能来治疗急性白血病的前景有望. 这种微管抑制剂提供了一个独特的机制,有可能克服对当前疗法的耐药性.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 尽管治疗方面取得了进展,但急性白血病仍然具有挑战性.
- 微管抑制剂是已知的癌症疗法,促使对新化合物的研究.
- C2E1是一种环[b]醇衍生物,正在研究其抗白血病潜力.
研究的目的:
- 为了研究C2E1对急性白血病的治疗潜力.
- 评估C2E1在分子,细胞和遗传层面的影响.
主要方法:
- 评估了C2E1对蛋白动态和白血病细胞活力的影响.
- 分析了C2E1对细胞亡,细胞周期进展,克隆性和迁移的影响.
- 研究了分子变化,包括DNA损伤,增殖标记和基因表达.
主要成果:
- C2E1诱导了管脱极化,并显著降低了白血病细胞活力.
- 它触发了细胞亡,细胞循环停止,并抑制了白血病细胞的克隆性和迁移.
- 分子分析揭示了C2E1诱导的DNA损伤和与细胞骨调节相关的基因表达改变.
结论:
- 通过多方面的细胞破坏,C2E1显示出显著的抗白血病特性.
- 它的独特机制可以克服与常规微管向药物相关的耐药性.
- C2E1是急性白血病新型抗癌疗法的有希望的候选者.
更多相关视频
07:30A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones
Published on: January 21, 2020
8.1K
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.1K
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Destabilization of Microtubules
2.7K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Positive Regulator Molecules
5.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
